FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140411181> ?p ?o ?g. }

• W2140411181 endingPage "701" @default.
• W2140411181 startingPage "692" @default.
• W2140411181 abstract "Sodium/glucose cotransporter 2 (SGLT2) is the predominant mediator of renal glucose reabsorption and is an emerging molecular target for the treatment of diabetes. We identified a novel potent and selective SGLT2 inhibitor, tofogliflozin (CSG452), and examined its efficacy and pharmacological properties as an antidiabetic drug. Tofogliflozin competitively inhibited SGLT2 in cells overexpressing SGLT2, and <i>K</i>_i values for human, rat, and mouse SGLT2 inhibition were 2.9, 14.9, and 6.4 nM, respectively. The selectivity of tofogliflozin toward human SGLT2 versus human SGLT1, SGLT6, and sodium/myo-inositol transporter 1 was the highest among the tested SGLT2 inhibitors under clinical development. Furthermore, no interaction with tofogliflozin was observed in any of a battery of tests examining glucose-related physiological processes, such as glucose uptake, glucose oxidation, glycogen synthesis, hepatic glucose production, glucose-stimulated insulin secretion, and glucosidase reactions. A single oral gavage of tofogliflozin increased renal glucose clearance and lowered the blood glucose level in Zucker diabetic fatty rats. Tofogliflozin also improved postprandial glucose excursion in a meal tolerance test with GK rats. In db/db mice, 4-week tofogliflozin treatment reduced glycated hemoglobin and improved glucose tolerance in the oral glucose tolerance test 4 days after the final administration. No blood glucose reduction was observed in normoglycemic SD rats treated with tofogliflozin. These findings demonstrate that tofogliflozin inhibits SGLT2 in a specific manner, lowers blood glucose levels by increasing renal glucose clearance, and improves pathological conditions of type 2 diabetes with a low hypoglycemic potential." @default.
• W2140411181 created "2016-06-24" @default.
• W2140411181 creator A5006408186 @default.
• W2140411181 creator A5018520479 @default.
• W2140411181 creator A5022193625 @default.
• W2140411181 creator A5022992447 @default.
• W2140411181 creator A5023513766 @default.
• W2140411181 creator A5028421346 @default.
• W2140411181 creator A5044498054 @default.
• W2140411181 creator A5047328032 @default.
• W2140411181 creator A5055024048 @default.
• W2140411181 creator A5058145690 @default.
• W2140411181 creator A5058248556 @default.
• W2140411181 creator A5065225304 @default.
• W2140411181 creator A5069739406 @default.
• W2140411181 creator A5086640824 @default.
• W2140411181 date "2012-03-12" @default.
• W2140411181 modified "2023-10-13" @default.
• W2140411181 title "Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice" @default.
• W2140411181 cites W1645918562 @default.
• W2140411181 cites W1961412792 @default.
• W2140411181 cites W1969979801 @default.
• W2140411181 cites W1984700778 @default.
• W2140411181 cites W1996185349 @default.
• W2140411181 cites W1998453182 @default.
• W2140411181 cites W2002959236 @default.
• W2140411181 cites W2003060007 @default.
• W2140411181 cites W2004021952 @default.
• W2140411181 cites W2004221267 @default.
• W2140411181 cites W2011063859 @default.
• W2140411181 cites W2019530219 @default.
• W2140411181 cites W2021955909 @default.
• W2140411181 cites W2026609170 @default.
• W2140411181 cites W2037810433 @default.
• W2140411181 cites W2046446546 @default.
• W2140411181 cites W2048870206 @default.
• W2140411181 cites W2050614267 @default.
• W2140411181 cites W2050915632 @default.
• W2140411181 cites W2057109662 @default.
• W2140411181 cites W2061092178 @default.
• W2140411181 cites W2066259921 @default.
• W2140411181 cites W2075033480 @default.
• W2140411181 cites W2082515526 @default.
• W2140411181 cites W2086812198 @default.
• W2140411181 cites W2103196856 @default.
• W2140411181 cites W2133469996 @default.
• W2140411181 cites W2134855422 @default.
• W2140411181 cites W2145442681 @default.
• W2140411181 cites W2149185387 @default.
• W2140411181 cites W2169237458 @default.
• W2140411181 cites W2171183320 @default.
• W2140411181 cites W2172296871 @default.
• W2140411181 doi "https://doi.org/10.1124/jpet.112.191593" @default.
• W2140411181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22410641" @default.
• W2140411181 hasPublicationYear "2012" @default.
• W2140411181 type Work @default.
• W2140411181 sameAs 2140411181 @default.
• W2140411181 citedByCount "129" @default.
• W2140411181 countsByYear W21404111812012 @default.
• W2140411181 countsByYear W21404111812013 @default.
• W2140411181 countsByYear W21404111812014 @default.
• W2140411181 countsByYear W21404111812015 @default.
• W2140411181 countsByYear W21404111812016 @default.
• W2140411181 countsByYear W21404111812017 @default.
• W2140411181 countsByYear W21404111812018 @default.
• W2140411181 countsByYear W21404111812019 @default.
• W2140411181 countsByYear W21404111812020 @default.
• W2140411181 countsByYear W21404111812021 @default.
• W2140411181 countsByYear W21404111812022 @default.
• W2140411181 countsByYear W21404111812023 @default.
• W2140411181 crossrefType "journal-article" @default.
• W2140411181 hasAuthorship W2140411181A5006408186 @default.
• W2140411181 hasAuthorship W2140411181A5018520479 @default.
• W2140411181 hasAuthorship W2140411181A5022193625 @default.
• W2140411181 hasAuthorship W2140411181A5022992447 @default.
• W2140411181 hasAuthorship W2140411181A5023513766 @default.
• W2140411181 hasAuthorship W2140411181A5028421346 @default.
• W2140411181 hasAuthorship W2140411181A5044498054 @default.
• W2140411181 hasAuthorship W2140411181A5047328032 @default.
• W2140411181 hasAuthorship W2140411181A5055024048 @default.
• W2140411181 hasAuthorship W2140411181A5058145690 @default.
• W2140411181 hasAuthorship W2140411181A5058248556 @default.
• W2140411181 hasAuthorship W2140411181A5065225304 @default.
• W2140411181 hasAuthorship W2140411181A5069739406 @default.
• W2140411181 hasAuthorship W2140411181A5086640824 @default.
• W2140411181 hasConcept C126322002 @default.
• W2140411181 hasConcept C134018914 @default.
• W2140411181 hasConcept C185592680 @default.
• W2140411181 hasConcept C2777180221 @default.
• W2140411181 hasConcept C2777538456 @default.
• W2140411181 hasConcept C2778199505 @default.
• W2140411181 hasConcept C555293320 @default.
• W2140411181 hasConcept C71924100 @default.
• W2140411181 hasConcept C90466245 @default.
• W2140411181 hasConcept C98274493 @default.
• W2140411181 hasConceptScore W2140411181C126322002 @default.
• W2140411181 hasConceptScore W2140411181C134018914 @default.
• W2140411181 hasConceptScore W2140411181C185592680 @default.

• next